154 related articles for article (PubMed ID: 10901159)
1. Reboxetine: its effects as measured by the Social Adaptation Self-evaluation Scale.
Healy D
Acta Psychiatr Scand Suppl; 2000; 402():45-51. PubMed ID: 10901159
[TBL] [Abstract][Full Text] [Related]
2. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
Andreoli V; Caillard V; Deo RS; Rybakowski JK; Versiani M
J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
[TBL] [Abstract][Full Text] [Related]
3. Assessment of social functioning in depression.
Bosc M
Compr Psychiatry; 2000; 41(1):63-9. PubMed ID: 10646621
[TBL] [Abstract][Full Text] [Related]
4. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.
Dubini A; Bosc M; Polin V
J Psychopharmacol; 1997; 11(4 Suppl):S17-23. PubMed ID: 9438229
[TBL] [Abstract][Full Text] [Related]
5. Do noradrenaline and serotonin differentially affect social motivation and behaviour?
Dubini A; Bosc M; Polin V
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S49-55; discussion S71-3. PubMed ID: 9169310
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale.
Bosc M; Dubini A; Polin V
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S57-70; discussion S71-3. PubMed ID: 9169311
[TBL] [Abstract][Full Text] [Related]
7. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.
Venditti LN; Arcelus A; Birnbaum H; Greenberg P; Barr CE; Rowland C; Williamson T
Int Clin Psychopharmacol; 2000 Sep; 15(5):279-89. PubMed ID: 10993130
[TBL] [Abstract][Full Text] [Related]
8. Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
Massana J
J Clin Psychiatry; 1998; 59 Suppl 14():8-10. PubMed ID: 9818624
[TBL] [Abstract][Full Text] [Related]
9. The antidepressant efficacy of reboxetine in patients with severe depression.
Montgomery S; Ferguson JM; Schwartz GE
J Clin Psychopharmacol; 2003 Feb; 23(1):45-50. PubMed ID: 12544375
[TBL] [Abstract][Full Text] [Related]
10. Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS).
Keller M
Gen Hosp Psychiatry; 2001; 23(1):15-9. PubMed ID: 11226552
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
Taner E; Demir EY; Cosar B
Adv Ther; 2006; 23(6):974-87. PubMed ID: 17276965
[TBL] [Abstract][Full Text] [Related]
12. Reboxetine: tolerability and safety profile in patients with major depression.
Tanum L
Acta Psychiatr Scand Suppl; 2000; 402():37-40. PubMed ID: 10901157
[TBL] [Abstract][Full Text] [Related]
13. From symptoms to social functioning: differential effects of antidepressant therapy.
Kasper S
Int Clin Psychopharmacol; 1999 May; 14 Suppl 1():S27-31. PubMed ID: 10468326
[TBL] [Abstract][Full Text] [Related]
14. Are there differences between serotonergic, noradrenergic and dual acting antidepressants in the treatment of depressed women?
Eker SS; Kirli S; Akkaya C; Cangur S; Sarandol A
World J Biol Psychiatry; 2009; 10(4 Pt 2):400-8. PubMed ID: 19670086
[TBL] [Abstract][Full Text] [Related]
15. Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?
Nelson JC; Portera L; Leon AC
Biol Psychiatry; 2005 Jun; 57(12):1535-42. PubMed ID: 15953490
[TBL] [Abstract][Full Text] [Related]
16. Basal prolactin values correlate with response to reboxetine treatment in major depression, but not with response to citalopram.
Moeller O; Hetzel G; Michael N; Rothermundt M; Arolt V; Erfurth A
Neuropsychobiology; 2005; 51(2):67-71. PubMed ID: 15741746
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
Papakostas GI; Nelson JC; Kasper S; Möller HJ
Eur Neuropsychopharmacol; 2008 Feb; 18(2):122-7. PubMed ID: 17719752
[TBL] [Abstract][Full Text] [Related]
18. Successful management of depression with reboxetine in a patient who developed Parkinsonism related to paroxetine use.
Kuloglu M; Caykoylu A; Ekinci O; Bayindirli D; Vural G; Deniz O
J Psychopharmacol; 2010 Apr; 24(4):623-4. PubMed ID: 19074535
[No Abstract] [Full Text] [Related]
19. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
Fava M; McGrath PJ; Sheu WP;
J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
[TBL] [Abstract][Full Text] [Related]
20. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine.
Nelson JC; Portera L; Leon AC
J Clin Psychiatry; 2005 Nov; 66(11):1409-14. PubMed ID: 16420078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
